Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GVGH Shigella sonnei 1790GAHB vaccine
- Development stage
- Phase 2
- Lead developer
- GSK Vaccines Institute for Global Health
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The GVGH Shigella sonnei 1790GAHB vaccine is an investigational prophylactic vaccine designed to prevent infection by Shigella sonnei, a major cause of bacillary dysentery (shigellosis). It is based on the Generalized Modules for Membrane Antigens (GMMA) technology, which utilizes outer membrane vesicles derived from genetically modified S. sonnei bacteria that express high levels of O antigen (OAg). The formulation contains GMMA proteins and aluminum hydroxide as an adjuvant. The primary mechanism involves stimulating the immune system to produce antibodies against the lipopolysaccharide (LPS) O antigen of S. sonnei, thereby conferring protective immunity through immunostimulation and antibody-mediated responses. Clinical studies have shown that the vaccine is immunogenic and well tolerated in adults[1][4][5][6][7]. Development has been led by GSK Vaccines Institute for Global Health (GVGH), with GlaxoSmithKline involved in manufacturing.
- Brand names
- GVGH S. sonnei 1790GAHB vaccine
- Other names
- Shigella sonnei GMMA-based vaccineS. sonnei 1790GAHBGMMA-based S. sonnei vaccine
Beyond the preview
Go deeper on GVGH Shigella sonnei 1790GAHB vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GVGH Shigella sonnei 1790GAHB vaccine.